| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4908 | SS-thujaplicinol | Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2) |
|
| DCC4909 | Sstr3-agonist-5c | Novel non-peptidic highly potent somatostatin receptor 3 (SSTR3) agonist |
|
| DCC4910 | Sstr3-antagonist-3a | Novel potent sstr3 antagonist, showing to reduce glucose excursion in a mouse oGTT assay |
|
| DCC4911 | Sstr5a | Novel somatostatin receptor subtype 5 antagonist, stimulating glucoseinduced GLP-1 secretion, reducing blood glucose in a gut- and GLP-1R-dependent manner |
|
| DCC4912 | St026567 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4913 | St029248 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4914 | St056083 | Novel inhibitor of the c-di-AMP synthetase DNA integrity scanning protein (DisA) in vitro |
|
| DCC4915 | St101036 | Novel potent mast cell (MC) activator, promoting de novo synthesis of cytokines and inducing the release of eicosanoids from human and mouse MCs |
|
| DCC4916 | st-1032 | Novel histamine H3 receptor ligand |
|
| DCC4917 | St1237 | Potent, direct, non-cytotoxic Arachidonate_5-lipoxygenase>5-lipoxygenase (5-LO) inhibitor |
|
| DCC4918 | St-161 | Antiviral agent against LASV and a number of other viruses in the Arenaviridae family |
|
| DCC4919 | St-1703 | Novel histamine H3 receptor ligand |
|
| DCC4920 | St-1892 | Novel highly potent and soluble partial FXR agonist |
|
| DCC4921 | St-198 | Seletive dopamine D3 receptors |
|
| DCC4922 | St-1992 | Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4923 | St-2001 | Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4924 | St-2262 | Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
| DCC4925 | St4070 | Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
|
| DCC4926 | St7710aa1 | Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
|
| DCC4927 | Sta-9584 | Novel tubulin-binding vascular disrupting agent (VDA) |
|
| DCC4928 | Stad-2 | Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
|
| DCC4929 | Stalobacin I | Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
| DCC4930 | Stanozolol [10418-03-8] | Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
|
| DCC4931 | Stat3 -in-11 | Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
| DCC4932 | stat3 Inhibitor 6 | Novel inhibitor of STAT3 signaling pathway |
|
| DCC4933 | Stat3-in-13r | Novel inhibitor of STAT3, targeting SH2 domain |
|
| DCC4934 | Stat3-in-3 | Novel potent and selective inhibitor of STAT3 |
|
| DCC4935 | Stat3-in-a69 | Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
| DCC4936 | Stat3-in-b9 | Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145 |
|
| DCC4937 | Stat5a-in-27 | Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t |
|
